Chromosomal Phasing Non-Invasive Prenatal Testing Market to Reach USD 1,270.0 million by 2036 as Single-Gene NIPT Adoption Accelerates Across Prenatal Genetics Programs

The global Chromosomal Phasing Non-Invasive Prenatal Testing (NIPT) Market is projected to grow from USD 639.6 million in 2026 to USD 1,270.0 million by 2036, registering a 7.1% CAGR during the forecast period. The market surpassed USD 597.2 million in 2025 and is expected to create an absolute opportunity of USD 630.4 million by 2036. Growth is being driven by rising adoption of parental haplotyping, expanding use of Single-Gene NIPT, and increasing demand for family-specific inherited disease risk assessment.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=15614

Key Market Highlights at a Glance

• Market valuation in 2025: USD 597.2 million
• Market size in 2026: USD 639.6 million
• Forecast market size by 2036: USD 1,270.0 million
• CAGR (2026-2036): 7.1%

• Absolute opportunity by 2036: USD 630.4 million
• Leading test type: Single-Gene NIPT (30.0% share)
• Leading technology: Parental Haplotyping (30.0% share)
• Leading indication: Monogenic Disorders (30.0% share)
• Leading end user: Hospitals (30.0% share)
• Fastest-growing country: Germany (9.6% CAGR)

Why Is the Chromosomal Phasing Non-Invasive Prenatal Testing Market Growing?
Several factors are accelerating adoption of chromosomal phasing NIPT solutions worldwide:
• Growing need for inherited disease risk assessment based on family history and carrier screening results
• Increasing use of parental haplotyping to determine fetal inheritance patterns without invasive procedures
• Rising demand for hospital-based prenatal genetics services with integrated counseling and follow-up support

Unlock 360° insights for strategic decision making and investment planning: https://www.factmr.com/checkout/15614

Shambhu Nath Jha, Senior Analyst at Fact.MR, commented: "Chromosomal phasing is helping prenatal testing move beyond common chromosome screening toward more personalized inherited-disease assessment. Market success will depend on reliable fetal DNA thresholds, fewer failed tests, strong parental-genetics interpretation, and clear communication distinguishing screening results from confirmed diagnoses."

Which Test Type Leads Market Share?
Single-Gene NIPT Leads the Market
Single-Gene NIPT is expected to account for 30.0% of the market in 2026, making it the largest test type segment.

The segment is benefiting from growing use in pregnancies where carrier screening or family history has already identified a specific inherited disease concern. Healthcare providers increasingly prefer targeted testing pathways that answer clearly defined genetic questions.

Key facts:

• Single-Gene NIPT market share: 30.0% in 2026
• Supports inherited disease assessment from maternal blood samples
• Increasingly used alongside carrier screening programs
• Expanding commercial availability through new gene-panel offerings

Why Does Parental Haplotyping Lead Technology Adoption?
Parental Haplotyping Holds the Largest Technology Share
Parental Haplotyping is projected to represent 30.0% of technology demand in 2026.

The technology provides family-specific inheritance mapping by determining whether disease-associated genetic variants have been transmitted from either parent to the fetus. This capability makes it highly valuable for monogenic disease assessment.

Key facts:

• Parental Haplotyping share: 30.0% in 2026
• Supports inheritance-resolved fetal risk assessment
• Enables family-specific genetic interpretation
• Complements sequencing, SNP analysis, and cell-free DNA workflows

Which Applications and End Users Dominate Demand?
Monogenic Disorders Lead Clinical Applications
Monogenic Disorders are anticipated to capture 30.0% of application demand in 2026.

Demand is increasing because testing often focuses on a known disease-causing variant already identified within a family.

Key facts:

• Monogenic Disorders share: 30.0%
• Expands prenatal risk assessment beyond trisomy screening
• Supports carrier screening follow-up programs

Hospitals Hold the Largest End-User Share
Hospitals are projected to account for 30.0% of end-user demand in 2026.
Hospitals provide integrated access to obstetric specialists, clinical laboratories, genetics experts, and patient counseling services.

Key facts:

• Hospitals share: 30.0%
• Strong referral networks support testing adoption
• Genetic counseling capabilities improve patient understanding

Gain Full Access to Market Forecasts and Key Drivers: https://www.factmr.com/report/chromosomal-phasing-non-invasive-prenatal-testing-market

Market Dynamics

Drivers

• Single-Gene NIPT adoption following carrier screening
• Growing use of parental haplotyping for inheritance tracking
• Expansion of prenatal genetics counseling services
• Defined public screening pathways and clinical governance
• Validation of expanded inherited-disease gene panels

Restraints

• Requirement for confirmatory invasive diagnosis after high-risk screening results
• No-call results caused by low fetal fraction levels
• Counseling and reimbursement challenges
• Regulatory caution surrounding expanded screening applications

Key Trends

• Expansion of single-gene prenatal testing panels
• Improved fetal-fraction reporting and laboratory transparency
• Fertility-clinic adoption in inherited-risk pregnancies
• Integration of advanced prenatal genetics counseling pathways

Regional and Country Outlook

Country growth projections include:

• Germany: 9.6% CAGR
• Brazil: 8.9% CAGR
• USA: 8.2% CAGR
• South Korea: 7.5% CAGR
• United Kingdom: 6.7% CAGR
• Japan: 6.0% CAGR

Germany leads global growth due to strong university-hospital genetics programs, structured prenatal referral systems, and clear pathways linking screening, counseling, and diagnosis.

Brazil is experiencing rapid expansion as private laboratories broaden access to inherited-disease testing and counseling services.

The United States benefits from active prenatal test developers, specialist maternal-fetal medicine networks, and ongoing clinical validation efforts for expanded testing panels.

South Korea continues to grow through concentrated hospital systems and established genomics infrastructure that facilitate adoption of advanced prenatal testing workflows.

The United Kingdom and Japan maintain steady growth through highly regulated screening pathways, evidence-based adoption models, and specialist prenatal care frameworks.

Competitive Landscape

Major market participants include:

• Natera, Inc. - SNP-based and LinkedSNP prenatal testing solutions
• BillionToOne, Inc. - UNITY prenatal testing and molecular counting platform
• Illumina, Inc. - sequencing platforms and prenatal testing infrastructure
• F. Hoffmann-La Roche Ltd. - molecular diagnostics and laboratory solutions
• BGI Genomics Co., Ltd. - genomics testing capabilities
• Laboratory Corporation of America Holdings (Labcorp) - national laboratory network
• Quest Diagnostics Incorporated - diagnostic and prenatal testing services
The competitive landscape is increasingly shaped by test accuracy, clinical validation, counseling support, inheritance-risk interpretation, and reporting quality rather than sequencing capability alone.

Discover the Latest Insights in the Healthcare Industry: https://www.factmr.com/industry/healthcare

FAQ
What is the Chromosomal Phasing Non-Invasive Prenatal Testing Market size by 2036?
The Chromosomal Phasing Non-Invasive Prenatal Testing Market is projected to reach USD 1,270.0 million by 2036.

What CAGR is expected for the market?
The market is forecast to expand at a CAGR of 7.1% between 2026 and 2036.

Which test type leads the market?
Single-Gene NIPT is expected to lead the market with a 30.0% share in 2026.

Which technology segment holds the largest share?
Parental Haplotyping is projected to account for 30.0% of technology demand in 2026.

Which application segment dominates demand?
Monogenic Disorders are anticipated to represent 30.0% of application demand in 2026.

Which end-user segment is the largest?
Hospitals are expected to hold the largest end-user share at 30.0% in 2026.

Which country is growing the fastest?
Germany is projected to be the fastest-growing country market with a CAGR of 9.6% through 2036.

Top Trending Reports:
Chromosomal Aberration Test Market: https://www.factmr.com/report/1160/chromosomal-aberration-test-market
HSV Testing Market: https://www.factmr.com/report/hsv-testing-market
Eye Testing Equipment Market: https://www.factmr.com/report/eye-testing-equipment-market
Blood Testing Devices Market: https://www.factmr.com/report/2680/blood-testing-devices-market

- Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com

About Fact.MR
Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

This release was published on openPR.